ASCO GI CANCERS 2023 HIGHLIGHTS.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 2, p. 112
- Publication type:
- Article
Works matching IS 21641153 AND DT 2023 AND VI 13 AND IP 2
Results: 8
1
2
New Oncology Drugs, New Indications, and New Formulations Approved by the FDA.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 2, p. 107
- Publication type:
- Article
3
Novel Use of Ravulizumab in Transplant-Associated Thrombotic Microangiopathy: Case Report.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 2, p. 102
- By:
- Publication type:
- Article
4
Palbociclib-Induced Hepatotoxicity in a Patient with Metastatic Breast Cancer: A Case Report.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 2, p. 96
- By:
- Publication type:
- Article
5
Oral Chemotherapy Program Metrics: Results of a National Survey.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 2, p. 85
- By:
- Publication type:
- Article
6
Incidence and Severity of Neuropathy with Concurrent Use of Voriconazole and Vincristine in Pediatric Patients with Cancer.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 2, p. 77
- By:
- Publication type:
- Article
7
Evaluation of Outcomes in Patients Who Received Bevacizumab for the Treatment of Brain Radionecrosis.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 2, p. 72
- By:
- Publication type:
- Article
8
Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders: A Single-Center Experience.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 2, p. 65
- By:
- Publication type:
- Article